Agenda

A focus on bladder, kidney and prostate cancers.

The 2026 World Conference on Genitourinary Cancers brings together multidisciplinary experts to explore innovation, evidence, and practical strategies that elevate care across prostate, bladder, and kidney cancers. The program moves in a logical progression from emerging technologies to real‑world clinical application, offering a focused and collaborative learning experience. Receive up to 10.5 CE credits.

2026 aGENDA

Explores how rapidly advancing technologies—especially artificial intelligence—are influencing imaging, pathology, and clinical decision‑making, with attention to both opportunities and limitations.
Reviews evolving systemic treatment modalities, comparing mechanisms, applications, and selection factors for modern therapeutic approaches used across GU cancers.
Highlights multidisciplinary management of high‑risk disease, demonstrating how coordinated workflows between specialties influence outcomes and patient experience.
Provides practical guidance on adapting evidence to daily practice, including dose adjustments, treatment holds, consolidative strategies, and evolving supportive care.
Addresses rare and less common GU histologies, outlining diagnostic and therapeutic challenges and how clinicians navigate limited evidence using multidisciplinary insights.
Examines emerging tools and capabilities shaping the next era of oncology practice, including advances in genomic testing, molecular diagnostics, imaging, digital health, and focal therapy strategies.
Discusses subtle but clinically meaningful factors in detection and recurrence monitoring, including biomarkers, imaging refinements, and considerations for high‑risk screening populations.
Explores how clinicians balance treatment intensity—escalation vs. de‑escalation—based on disease biology, patient characteristics, and evolving evidence across tumor types.
Outlines real‑world integration of combination approaches and therapeutic partners, offering practical insights for community and academic settings.
Summarizes the evolving treatment landscape with concise updates on new data, shifting standards, and upcoming developments for major GU cancers.
Synthesizes program themes through applied, case‑driven discussions that demonstrate multidisciplinary coordination and practical decision‑making across complex scenarios.
Concludes with an engaging educational finale designed to reinforce learning and celebrate collaborative progress within the GU oncology community.

The 2026 program delivers a comprehensive, forward‑looking experience that bridges scientific advancement with real‑world practice, emphasizing the value of multidisciplinary care and equipping clinicians with actionable insights to improve outcomes across the genitourinary cancer spectrum.

Thursday, December 3, 2026

Welcome Day

Poster Session & Welcome Reception

friday, December 4, 2026

day one

The New Frontier of Diagnostics in GU Cancers: How Are They Informing Practice?

King Kong vs Godzilla: ADC vs RLT

Multidisciplinary Care of High-Risk Patients in GU Cancers

Rubber Meets the Road for Real-World Management in GU Cancers – Part I

How I Manage Rare Histologies

Tools for Tomorrow’s Oncologist

Saturday, December 5, 2026

day two

The Big Deal about Small Things in GU Cancers

Strategy and Balance: Finding the Optimal Intensity

Rubber Meets the Road for Real-World Management in GU Cancers – Part 2

The Evolving Landscape

Application Panel

Final World GU-Pardy!

Thursday, December 3, 2026

Welcome Day

Poster Session & Welcome Reception

friday, December 4, 2026

day one

Faculty & Fellows Breakfast

Welcome & Opening Remarks

Chairs:
Alicia Morgans, MD, MPH, FASCO (Harvard Medical School)
Daniel George, MD (Duke Cancer Institute)

The New Frontier of Diagnostics in GU Cancers: How Are They Informing Practice?

Session Chair: Alan Bryce, MD (City of Hope)

ctDNA Guided Treatment Decisions

Stephanie Berg, DO (Harvard Medical School)

Incorporating New Biomarkers

Himisha Beltran, MD (Harvard Medical School)

AI MD: Is It Ready For Primetime?

Michael Lattanzi, MD (Texas Oncology)

AI Decision-Making Tools: Advantages and Limitations

Daniel Spratt, MD (University Hospitals Seidman Cancer Center)

Panel Discussion and Q&A

Edward Arrowsmith, MD, MPH (Tennessee Oncology)
Bradley Somer, MD (West Cancer Center & Research Institute)

King Kong vs Godzilla: Antibody Drug Conjugates & Radioligand Therapies

Session Chair: Evan Yu, MD (University of Washington / Fred Hutch Cancer Center)

ADCs in Bladder Cancer

Amanda Nizam, MD (Cleveland Clinic)

Radioligand Therapy in Prostate

Atish Choudhury, MD, PhD (Harvard Medical School)

ADC vs RLT in Kidney

Eric Jonasch, MD (MD Anderson Cancer Center)

Bispecifics vs CAR-T Disruption

Benjamin Garmezy, MD (Sarah Cannon Research Institute)

Panel Discussion and Q&A

Elizabeth Kessler, MD (University of Colorado Health)
Ulka Vaishampayan, MD, FASCO (University of Michigan)

Networking Break

Multidisciplinary Care of High-Risk Patients in GU Cancers

Session Chair: Ashley Ross, MD, PhD (Northwestern Medicine)

LUGPA Community Perspective Prostate

Benjamin Lowentritt, MD, FACS (Chesapeake Urology Associates)

High-Risk Bladder Cancer

Jason Efstathiou, MD, DPhil, FASTRO, FACRO (Mass General Brigham Cancer Institute)

High-Risk Kidney Cancer

Naomi Haas, MD (University of Pennsylvania)

Nurse Navigation - Corralling the Team/Patient Support

Stacy Walker, FNP-BC (Harvard Medical School)

Panel Discussion and Q&A

Jiaoti Huang, MD, PhD (Duke Cancer Institute)
Vijay Gunuganti, MD (Texas Oncology)

Lunch Industry Symposium (Non-CE)

Rubber Meets the Road for Real-World Management in GU Cancers - Part I

Session Chair: Elisabeth Heath, MD, FACP (Mayo Clinic)

Alternative Dosing of Systemic Therapies

Pedro Barata, MD, MSc (University Hospitals Seidman Cancer Center)

Treatment Holidays - When Do We Hold Outside of PD?

Michael Harrison, MD (Duke Cancer Institute)

Consolidative Treatments - When Do We Combine Modalities?

Andrew Hahn, MD (MD Anderson Cancer Center)

Remastering or Reboot in Supportive Care

Elizabeth Wulff, MD (University of Kansas Medical Center)

Panel Discussion and Q&A

David Slosky, MD (Tennessee Oncology)
Kristen Nuspl, PA-C (Harvard Medical School)

How I Manage Rare Histologies

Session Chair: Robert Dreicer, MD, MS, MACP, FASCO (University of Virginia Health)

Advancements in Small Cell Prostate Cancer

Ana Aparicio, MD (MD Anderson Cancer Center)

Management of Metastatic Chromophobe RCC

Pavlos Msaouel, MD, PhD (MD Anderson Cancer Center)

Management of Adenocarcinoma of the Bladder

Arlene Siefker-Radtke, MD (MD Anderson Cancer Center)

Panel Discussion and Q&A

Darren Feldman, MD (Memorial Sloan Kettering Cancer Center)
Brenda Martone, APRN (Northwestern Medicine)
Jeannie Hoffman-Censits MD (Johns Hopkins Kimmel Cancer Center)

Networking Break

Tools for Tomorrow's Oncologist

Session Chair: (Sandy Srinivas, MD Stanford University Medicine)

Genetic Testing Evolution: Right Test, Right Patient

Benjamin Maughan, MD, PharmD (UT Health San Antonio)

The Evolving PETshop

Scott Tagawa, MD, MS, FACP, FASCO (Weill Cornell Medicine)

EMR: Friend or Foe

Brooke Looney, PharmD, CSP (Vanderbilt University Medical Center)

Focus on Focal Therapy

Mai Anh Huynh, MD, PhD (Mass General Brigham Cancer Institute)

Q&A

Keynote Presentation (Non-CE)

Alex Sheen

TEDxTalk speaker, author, podcast host, internationally-recognized humanitarian, and Founder of the because I said I would movement.

Saturday | August 23

Breakfast

Tools for Tomorrow's Oncologist

CHAIR: Katy Beckermann, MD, PhD (Tennessee Oncology)

Role of Precision Medicine

Ulka Vaishampayan, MD (University of Michigan)

Trials in Progress in Early-Stage Therapeutics

Elisabeth Heath, MD (Mayo Clinic)

Patient Frailty/FIT Levels

Stephanie Berg, DO (Harvard Medical School)

Palliative Care & Decision Making

Elizabeth Wulff-Burchfield, MD (University of Kansas)

Implementing Pathways in an Evolving Landscape

Lisa Raff, PharmD (OneOncology)

Improving Communication in a Multidisciplinary Environment

Kelvin Moses, MD, PhD (Vanderbilt University Medical Center)

Q&A

Networking Break

Strategies for the Implementation of MRD in GU Cancers

CHAIR: Benjamin Maughan, MD (Huntsman Cancer Institute)

Defining MRD

Alan Tan, MD (Vanderbilt University Medical Center)

Using ctDNA to measure MRD in Bladder Cancer

Elizabeth Plimack, MD (Fox Chase Cancer Center)

What's Different with MRD in Prostate?

Michael Schweizer, MD (Fred Hutch Cancer Center)

Controversies in Imaging MRD: PSMA PET and Biochemical Recurrence

Ravi Madan, MD (National Institutes of Health)

How Can We Better Measure MRD in Kidney?

Brian Rini, MD (Vanderbilt University Medical Center)

Panel Discussion and Q&A

Jeffrey Yorio, MD (Texas Oncology)

Special Session

Introduction

Daniel George, MD (Duke Cancer Center) & Alicia Morgans, MD, MPH, FASCO (Harvard Medical School)

Fireside Chat with Robert Califf, MD, MACC, former FDA Commissioner

Robert Califf, MD, MACC (Duke University Medical Center)

Lunch Symposium (Non-CE)

Case-Based Real-World Management and Therapeutic Interventions in GU Cancers- Part 2

CHAIR: Edwin Posadas, MD (Cedars Sinai Medical Center)

Case-Based Approach to PARP Inhibitors in Prostate Cancer

Chandler Park, MD (Norton Healthcare)

Case-Based Approach to Kidney Cancer

Hans Hammers, MD, PhD (UT Southwestern Medical Center)

Bladder MIBC Systemic Therapy and Outcomes

Jacqueline Brown, MD (Winship Cancer Institute of Emory University)

Panel Discussion and Q&A

Michael Lattanzi, MD (Texas Oncology)

Early-Stage Therapeutics: New Drugs in the Contemporary Landscape

CHAIR: Robert Dreicer, MD (University of Virginia)

Emerging Approaches to Bladder Cancer

Karine Tawagi, MD (University of Illinois at Chicago)

Emerging Approaches to Prostate Cancer

Benjamin Garmezy, MD (Sarah Cannon Research Institute)

Emerging Approaches to Kidney Cancer

Eric Jonasch, MD (MD Anderson Cancer Center)

Harnessing Resistance to Immunotherapy Approaches in Kidney Cancer

David Braun, MD, PhD (Yale Medicine)

Q&A

Networking Break

Applying the Good News into Everyday Practice

CHAIRS: Charles Ryan, MD (Memorial Sloan Kettering Cancer Center) & Alicia Morgans, MD, MPH, FASCO (Harvard Medical School)

Monday Morning Quick Start

World GU-Pardy

HOST: Mark Pomerantz, MD (Harvard Medical School)

Farewell Reception

Experience Nashville, TN

Come for the education. Stay for the fun.